Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2021.02.035DOI Listing

Publication Analysis

Top Keywords

mobile health
12
role mobile
8
ait
5
health technologies
4
technologies stratifying
4
stratifying patients
4
patients ait
4
ait cessation
4
cessation aria-eaaci
4
aria-eaaci perspective
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!